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Abstract
Background: CD4+ T-lymphocyte count (CD4 count) is a standard method used to monitor HIV-infected patients during
anti-retroviral therapy (ART). The World Health Organization (WHO) has pointed out or recommended that a handheld,
point-of-care, reliable, and affordable CD4 count platform is urgently needed in resource-scarce settings.
Methods: HIV-infected patient blood samples were tested at the point-of-care using a portable and label-free microchip
CD4 count platform that we have developed. A total of 130 HIV-infected patient samples were collected that included 16
de-identified left over blood samples from Brigham and Women’s Hospital (BWH), and 114 left over samples from Muhimbili
University of Health and Allied Sciences (MUHAS) enrolled in the HIV and AIDS care and treatment centers in the City of Dar
es Salaam, Tanzania. The two data groups from BWH and MUHAS were analyzed and compared to the commonly accepted
CD4 count reference method (FACSCalibur system).
Results: The portable, battery operated and microscope-free microchip platform developed in our laboratory (BWH) showed
significant correlation in CD4 counts compared with FACSCalibur system both at BWH (r = 0.94, p,0.01) and MUHAS
(r = 0.49, p,0.01), which was supported by the Bland-Altman methods comparison analysis. The device rapidly produced
CD4 count within 10 minutes using an in-house developed automated cell counting program.
Conclusions: We obtained CD4 counts of HIV-infected patients using a portable platform which is an inexpensive (,$1
material cost) and disposable microchip that uses whole blood sample (,10 ml) without any pre-processing. The system
operates without the need for antibody-based fluorescent labeling and expensive fluorescent illumination and microscope
setup. This portable CD4 count platform displays agreement with the FACSCalibur results and has the potential to expand
access to HIV and AIDS monitoring using fingerprick volume of whole blood and helping people who suffer from HIV and
AIDS in resource-limited settings.
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Introduction
More than 30 million human immunodeficiency virus (HIV)-
infected people live in the sub Saharan Africa, yet it is estimated
that only one in ten persons infected with HIV has been tested and
knows their HIV status [1,2,3,4,5,6,7]. Effective antiretroviral
therapy (ART) for HIV has been available in developed countries
for more than a decade and free of charge through philanthropic
resources such as Bill and Melinda Gates Foundation, Clinton and
Davis Duke, and governmental resources such as President’s
Emergency Fund for AIDS Relief (PEPFAR) [8]. However, in
Africa, less than 4 out of 10 people who need a treatment are
actually receiving ART [9]. Part of the problem associated with
existing ART delivery services are the limitations of conventional
methods to diagnose and monitor HIV-infected individuals living
in rural communities.
According to the National AIDS control program (NACP)
guidelines, ART is initiated for HIV-infected individuals with
CD4+ T lymphocyte counts below 350 cells per microliter of
blood [1,2,3,6,10,11], and 500 cells per microliter threshold is
commonly used to increase patient monitoring intensity [12].
Guidelines also require that patients should be regularly
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monitored for CD4+ T-lymphocyte counts at 6-month intervals.
The current gold standard methodology for measuring CD4+ T-
lymphocyte counts in whole blood is the fluorescent activated cell
count and sorting systems (FACS) [3,10,13]. However, these
systems face significant challenges in terms of scalability and
applicability including high equipment cost, requirement for
laboratory space, inadequate number of trained laboratory
personnel, lack of reliable and regular preventive maintenance
service and limited portability.
HIV infection has reached epidemic proportions in Tanzania
with an estimated 1.3 million patients living with HIV/AIDS.
Effective antiretroviral therapy (ART) for HIV has been
available in Tanzania for more than a decade. However, it is
estimated that less than 20% of all the infected individuals in
Tanzania are currently receiving treatment, the most affected
persons are living in rural and hard to reach communities. A
microchip test that is portable and affordable has potential to
impact HIV monitoring at all levels possibly with a higher
impact at the dispensary level.
To increase access to HIV and AIDS care and to improve
treatment outcomes requires development of inexpensive moni-
toring tools for resource-limited countries [13,14,15,16]. The
World Health Organization has stated that there is an urgent need
for a handheld, point-of-care (POC), reliable, affordable CD4 T-
cell count device for use in resource-limited regions [13]. While
lower test costs (,10 USD) are available in resource-limited
countries at central laboratories, these costs still remain unafford-
able for many patients. In addition, maintenance related expenses
are also significant. Therefore, there is a need for affordable tests
that can be performed at the POC in resource-scarce settings at all
levels especially as we strive to move further down the healthcare
delivery services.
The challenges with delivering healthcare at the POC in
developed world settings include ease-to-use, sample processing,
need for skilled health care workers, portability, and test
turnaround time (Table 1) [17]. These factors have long
constituted a bottleneck for recent microfluidic and lab-microchip
type platforms to be translated to the bed-side as applicable
diagnostic methodologies. These POC challenges adopt an
insurmountable silhouette at the resource-constrained settings,
where additional challenges are encountered. The difficulties
associated with resource-limited POC healthcare delivery involve
undependable electricity, demanding portability requirements on
devices and readers, and limitations on the use of peripheral
devices [3,13,17]. These interdependent challenges alter the
parameters for POC device design. Therefore, we need to design
new methodologies with practical thinking strategies to address
problems that go beyond the developed world geared engineering
and healthcare system [18]. These factors all broadly define the
poor performance encountered by well-operating, lab-designed
machinery in such resource-limited settings. Furthermore, fluo-
rescent labeling of cells for detection and enumeration present
significant challenges in these settings [6,11,17,19]. Therefore,
label-free approaches with simple imaging methods are needed at
the resource limited POC settings. Taking on these intriguing
biomedical, engineering and design challenges [20,21], we here
report clinical results from Tanzania using a POC CD4 count
microchip, which is an inexpensive (,$1 material costs),
disposable device that uses a volume of whole blood sample
(,10 ml) without any sample pre-processing. Our test results in
BWH and Tanzania have shown that the device produces CD4 T-
cell counts that are statistically comparable to FACSCalibur
results.
Methods
Study population and sample collection
De-identified left-over EDTA whole blood samples were
obtained from HIV-infected female and male patients between
the ages of 14 and 37, who were enrolled in the Harvard PEPFAR
supported HIV and AIDS care and treatment centers in Dar es
Salaam, Tanzania. To minimize additional time and workload of
both the patient and clinic staff our study team used whole blood
samples collected from de-identified HIV-infected patients during
routine patient care visits at the site clinics. Left over whole blood
samples for testing were taken from existing routine collection
procedures during processing at the central laboratory at
Muhimbili University of Health and Allied Sciences (MUHAS),
in Dar es Salaam, Tanzania, which did not require an additional
blood draw from patients. Out of 130 samples included in the
testing, 114 de-identified samples were selected randomly by the
study coordinator at the central laboratory, among the samples
that were received from each of the site clinics on a daily basis for
consecutive two weeks. Sixteen de-identified left over blood
samples were obtained from Brigham and Women’s Hospital in
Boston, USA. The existing HIV and AIDS care and treatment
program specimen tracking system was used to verify dispatch and
receipt of the whole blood specimens.
Ethics
The studies described here were performed under the approval
of the following Institutional Review Boards (IRB): Harvard
School of Public Health, Partners Human Research Committee,
and Muhimbili University of Health and Allied Sciences
Directorate of Research and Publications. Prior to the studies,
the IRBs approved ethical clearance and determined that the
research activities did not meet the definition of human subjects
research for the following reasons: 1) there was no intervention of
interaction with a living person for this research, and 2) there was
no identifiable personal information obtained for this research in a
form that can be associable with the individuals from whom the
blood samples were obtained. This determination was based upon
the U.S. Department of Health & Human Services Office for
Human Research Protections Human Subject Regulations
Decision Charts.
Microfluidic CD4 T-cell Count System
The microchip that captured CD4 cells was directly imaged
with a portable, battery operated CCD imaging platform and cells
were counted by automatic cell count software within a minute
without the need for a labeling process (Fig. 1). To image shadow
patterns of captured cells (Fig. 1a) with the CCD image sensor
(Fig. 1b, KODAK, KAI-11002, Rochester, NY), one gray color
image of the entire channel surface was taken (Fig. 1c–e). The
sensor featured more than 11 million square pixels (9 mm size),
across the active sensor array area, 37.25 mm625.70 mm
(Fig. 1d). The large active sensor area of the CCD enabled us
to use standard microscope cover slides (24 mm635 mm6
0.10 mm) with a thickness of 0.10,0.15 mm as the microfluidic
channel surface. The white light, emitted by a LED (276-0024,
high brightness white LED, RadioShack), passes through the
PMMA cover, reaches bottom glass surface of the microfluidic
channel and the captured cells on this surface. Lensless image
represented the diffracted shadow signal of the cell shape (Fig. 1e).
When the distance between the captured cells and CCD surface
was increased, the ring diameter of shadow image increased. This
effect was observed till the signal-to-noise between the shadow and
background light intensity reached to the CCD detection limit.
CD4 Count with Portable Microchip in Tanzania
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The system was designed to be adopted for POC testing, which
was composed of a black box containing a CCD sensor and a
mobile computer that weighed about 1 kg.
Fabrication and Operation of the Portable Microchip
Platform
Detailed description and illustration of device fabrication
(Table S1 and Fig. S1), preparation (Fig. S3 and Table S2),
and the standard operating procedures (Table S3) can be found
in Text S1, which were based on our previous studies [14]. The
microfluidic whole blood CD4 counting operation is outlined in
Figure 2, which was performed by minimally trained personnel
at MUHAS (Table S3). Briefly, the microfluidic chips were
removed from their vacuum sealed packages (Fig. S2 and
Fig. 2a), the capture antibody was injected into the chips
followed by a brief washing step (Table S2 and Fig. 2b), a one
step whole blood injection was performed (Fig. 2c), and the
microfluidic chip was imaged using a portable CCD based
imaging platform (Fig. 2d). The gravitational flow required
filling 50 mL of whole blood into the pipette directly on top of the
inlet of the device without additional sample handling or
processing (Fig. 2b&c). The pipette was removed from the inlet
as soon as the channel got fully filled with the whole blood
indicated by the red color. This process led to an estimated 8 mL
of whole blood to pass through the device in MUHAS tests. In
BWH tests, the volume of blood introduced into the channels was
controlled with automated pipettes to be 6 mL per channel. The
cell counts obtained from the microchips were normalized with
the total blood volume to convert the results to number of cells
per microliter of whole blood.
Automated CD4 Cell Counting in CCD images
An automated cell counting program was developed in
MATLAB (Mathworks Inc., Natick, Massachusetts) to resolve a
threshold signal level, which then determined the boundaries
between the cell membranes and the background. The CCD
shadow images were used to count the cells and to characterize a
distribution of captured cells using image recognition based
automated counting software. Automatic cell counting program
was designed based on pattern matching (Fig. 3a). In this method,
randomly selected CCD images of cells (a library of 50 images)
were evaluated to match the specific cell type. The matching
values from shadow imaging were obtained and quantified
(Fig. 3b). Based on a 50% matching value threshold between a
library image and the shadow microchip image, the captured cells
were detected and counted (Fig. 3c). Total number of CD4+ T-
lymphocytes obtained from the microfluidic device by counting
cell shadow images and the flow cytometry results (as a gold
standard) were compared.
Determination of CD4 Counts In Whole Blood Samples
with FACS
The whole blood sample was analyzed using similar reference
flow cytometry method at the two study sites to enumerate the
CD4+ T-lymphocytes. The flow cytometric measurements were
performed on a FACSCalibur (Beckton Dickinson Immunocyto-
metry System (BDIS, San Jose, CA) instrument using BD
CellQuest Pro Software. The flow cytometer was calibrated using
standardized bead kit (FACS TruCOUNTTM, BD Biosciences,
Mountain View, CA). CD4-Chex Plus BC (Streck, NE, USA)
controls (low and high) were run every day in the FACSCalibur
system at MUHAS lab before patient samples are run to ensure
accuracy and reliability of lab results. MUHAS laboratory also
participates in the proficiency testing program called UK NEQAS
(United Kingdom National External Quality Assessment Service)
where a panel of whole blood samples were received, analyzed in
the FACSCalibur system with a good performance report. The
CD4 counts were reported as cells per microliter of whole blood
sample.
Statistical Analyses
We tested de-identified left over whole blood samples collected
from adult patients at BWH (n= 16) and at MUHAS (n= 114).
We validated CD4+ T cell counts from the microchips in
comparison to the FACSCalibur results using the Pearson
product-moment correlation coefficient and Bland-Altman anal-
ysis. Statistical significance threshold was set at 0.01 (p,0.01). The
analyses were performed with Minitab (Release 14, Minitab Inc.,
State College, PA, USA). By validating a microchip CD4 count
platform against the FACSCalibur system, we aimed to analyze
how much the microchip method is likely to differ from the
reference method. The used validation procedures were as follows
[14]: 1) Assessing the linear regression between the microchip and
FACSCalibur counts, 2) assessing the Pearson product moment
Table 1. Comparison for the design requirements and operational demands of a POC monitoring device based on World Health
Organization (WHO) Standards for POC healthcare delivery at resource-scarce settings, and conventional devices at developed
world settings.
Resource-Scarce Settings Developed World Settings
Cost Inexpensive per test; disposable; maintenance free
or minimal inexpensive maintenance
Expensive per test; costly to maintain
Personnel Needs Minimally training; easy to maintain and operate Requires highly-trained personnel
Environmental Conditions Functional at high temperatures and high humidity
conditions
Room temperature and regular humidity levels
Infrastructure Battery operable without dependence on constant
electrical supply
Needs advanced and reliable infrastructure without
power outages
Accessibility Portable; deliverable to end users as a handheld
system without a need for centralized hospitals or clinics
Performed at established hospitals and clinics beyond
the district level
Accuracy & Precision Moderate to high to satisfy the minimal requirements
of clinical decision making
High
Throughput High High
doi:10.1371/journal.pone.0021409.t001
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correlation coefficient, r, between the two methodologies, 3)
Computing the difference and the mean between FACSCalibur
and microchip device for each specimen, 4) Generating a scatter
plot with differences for each specimen on the Y-axis plotted
against the means for each corresponding specimen on the X-axis,
5) Calculating the average difference between microchip devices
against the FACSCalibur count and the standard deviation of the
differences. The regression curves were generated using results
obtained from microchips each treated with the similar volume of
blood sample. The microchip measurements were normalized by
the estimated blood volume processed inside microfluidic channel
(8 mL) based on the gravitational flow. The agreement between the
two methods was evaluated by Pearson product-moment correla-
tion coefficient and Bland-Altman analysis with statistical
significance threshold set at 0.01 (p,0.01). The Bland-Altman
comparison analysis method was used for the repeatability of the
method using residual analysis by comparison to the gold standard
method. The coefficient of repeatability was calculated as 1.96
times the standard deviations of the differences between the two
measurements. In this analysis, a mean difference of zero infers
that the tested approach is unbiased with respect to the standard.
A clinically acceptable range would indicate the range within
which the difference would fall approximately 95% of the time. If
the mean difference and the limit of agreement are within the
clinically acceptable range, then the tested technique is deemed
comparable to the standard technique.
Figure 1. Depiction of the working principle of CD4+ T-lymphocyte counting microchip platform for the POC. (a) Shadow images of
captured cells were obtained using a large area CCD image sensor (24634 mm, 10 mega pixel). A pinhole LED (Light Emitting Diode) was used as a
light source. The POC platform has following two main processes. First, a microfluidic chip captured target CD4+ cells from unprocessed fingerprick
volume of HIV-infected whole blood by anti-CD4 antibody which was immobilized on the microchip surface. Second, the captured cells were imaged
using the wide field of view (FOV) lensless CCD platform within a second. White light generated from LED light source went through a 100 mm
pinhole and illuminated captured cells. Cell shadows were automatically detected and rapidly counted by automated image recognition software on
a portable laptop computer. (b) Schematic representation and drawing of the lensless imaging system for microfluidic CD4 count, (c) Photograph of
entire POCT CD4 imaging system, (d) microfluidic CD4 chip on top of CCD sensor inside a black box, (e) lensless imaging and magnified image
represents the diffracted shadow signal of the cell shape. Scale bar is 200 mm. Entire platform setup and operational details were shown in Text S1.
doi:10.1371/journal.pone.0021409.g001
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Results
An overview of microfluidic CD4 T cell count device and whole
blood processing procedure is shown in Fig. 1. Shadow images
(Fig. 1a) of captured cells from unprocessed volume of whole
blood were obtained using a large area CCD image sensor
(Fig. 1b–e) within a second by minimally trained personnel at
Tanzania (Fig. 2). Cell shadows were automatically detected and
counted by image recognition software (Fig. 3). Microchip
measurements correlated significantly with FACSCalibur counts,
when they were conducted at BWH (Fig. 4a, r: 0.94, p,0.01).
When the microchips were transported to Tanzania over 48 hours
on dry ice in a plane setting, the correlation coefficient between
the microchip and the FACSCalibur system counts were
statistically significant, however, with a lower correlation coeffi-
cient for the measurements that were performed at MUHAS
laboratory (Fig. 4b, correlation coefficient: 0.49, p,0.01). The
result of the Bland-Altman Analysis showed that no dependency of
the captured CD4 T cell count on the measurement magnitude
was observed in the case of BWH measurements (Fig. 4c). The
mean bias was +76 cells/mL of blood in microchip counts
compared to FACS counts at BWH. On the other hand, Bland-
Altman Analysis showed a bias towards higher measurements in
MUHAS results, while the mean bias was as low as +23 cells/mL of
blood in microchip counts compared to FACS counts (Fig. 4d).
Discussion
In the developed CD4 T cell count system, even though the
resource-limited environmental factors were observed to adversely
affect the operation, microchip CD4 T cell counts showed a
correlation and agreement with the FACSCalibur results. The
microchip CD4 counts were observed to highly correlate with the
FACSCalibur counts (correlation coefficient: 0.94, p,0.01) when
the measurements were performed at BWH by highly trained
healthcare personnel. On the other hand, microchip CD4 counts
that were performed at MUHAS using blood samples showed a
significant but lower level of correlation with the FACSCalibur
results (correlation coefficient: 0.49, p,0.01). These observed
differences in correlation between the BWH and MUHAS tests
could be explained by the environmental and the operator-
dependent factors present under the real world conditions of
resource limited settings.
The tests performed at BWH were carried out by highly trained
individuals on microfluidic techniques. The operators in Tanzania
were trained over a short course lasting about 30 minutes. These
operators followed clearly written standard operating procedures
(Text S1). For instance, automated pipettes were used at BWH
tests, which enabled accurate and uniform flow control through
the microfluidic channels at every stage of operation. It has been
shown that uniform flow yields improved results compared to
manual or gravity driven flow in microfluidic systems as also
reflected in our results. In addition, the microchips that were used
at BWH were freshly built and did not undergo the travel
conditions and long durations of intercontinental shipment (24–
72 hours). The microchips that were used at MUHAS, which were
built at BWH and transferred to Tanzania on dry ice, could
potentially influence the CD4 capture and count efficiency. All
these factors reflected the challenges of delivering affordable
healthcare in resource limited settings. Therefore, we converge
that these factors need to be further evaluated and resolved to
increase the operational efficiency of POC devices.
It should be noted that the BWH patients were already under
ART treatment and therefore had high CD4 counts (between 542
and 3236 CD4 counts per microliter of blood, Fig. 4a&c). The
Tanzania patient samples showed lower range of CD4 counts
(Fig. 4b&d). Therefore, we have evaluated the sensitivity of the
developed microfluidic CD4 count system with the Tanzania
patient samples for the clinically relevant CD4 count threshold
values (i.e., ,350 cells/ml to initiate ART, and ,500 cells/ml to
Figure 2. Overview of Microfluidic CD4 counting chip preparation, blood injection, and lensless imaging procedures by minimally
trained personnel at MUHAS. (a) Unpacking of the microfluidic chips, (b) antibody injection, (c) one step blood injection, (d) microfluidic CD4
count chip imaging using a point-of-care portable, battery operated lensless CCD based imaging platform.
doi:10.1371/journal.pone.0021409.g002
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increase patient monitoring intensity) [12]. The CD4 count
microfluidic chip developed in this study displayed 41% sensitivity
in detecting the CD4 counts less than 350 cells/ml in Tanzania
blood samples after correcting for the bias (+23 cells/ml)
determined with Bland-Altman analysis (Fig. 4d). On the other
hand, the detection sensitivity was as high as 87% for CD4 counts
less than 500 cells/ml after corrections for the bias. The lower
sensitivity in the case of 350 cells/ml threshold was mostly due to
the storage conditions of the microchips, where we preferred not
to transfer them on cold chain to see the real impact under non-
ideal storage conditions. Hence, antibody denaturation most likely
caused lower capture efficiency and detection sensitivity than the
BWH results as we had anticipated. As a solution to this problem,
it has been shown that sensitive immunologic and biochemical
reagents in microfluidic systems (e.g., antibodies) can be
lyophilized to significantly increase the shelf life of the test system
[22,23].
The microchip platform presented here weighed 1 kg, and it
was attached to a laptop system to acquire the shadow images of
captured cells and count the CD4 T cells using automated
software without the need for cell labelling. This whole system was
battery operable and portable. The CD4 count system has the
Figure 3. The typical output of automatic CD4 cell counting program based on pattern matching. (a) library images of cell types (a total
50 different images), (b) matching values compare an obtained shadow image and cell library images, (c) result of cell shadow image recognition
using four different types of library cell patterns. The detected cells were marked with color coding to each library image that they were best
matched using standard pattern recognition matching methods in MATLAB.
doi:10.1371/journal.pone.0021409.g003
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potential to be further miniaturized by replacing the laptop and
the imaging setup with smaller handheld units such as cell phones
with cameras indicating the future potential of such a system.
Further, the microchip can be integrated with a simple aspiration
system, where a single drop of blood can be introduced into the
microchip. These developmental stages can bring this portable
system closer to a commercially available product that can be
broadly used in resource-limited settings. Further, we anticipate
that these cost reductions in medical testing and enhancements in
POC diagnostics and monitoring technologies will also impact the
developed world healthcare delivery posing a broad interest for the
general public.
In conclusion, we have performed for the first time label-free
(fluorescent-free) CD4 T-lymphocyte counts from HIV-infected
patient blood with a disposable microchip system in the USA and
in Tanzania. Our results showed that portable CD4 capture and
counting devices are feasible and applicable at the POC settings.
The capture efficiency of the developed microchips was observed
to be dependent on cell concentration, environmental factors and
operational variations. Therefore, detection systems specifically
Figure 4. Comparison of microchip and Fluorescent Activated Cell Sorting (FACS) CD4+ T-lymphocyte counts for HIV-infected
patient whole blood samples. The measurements were performed at BWH (Brigham and Women’s Hospital, Boston, MA) and MUHAS (Muhimbili
University of Health and Allied Sciences, Dar es Salaam, Tanzania). FACSCalibur counts were used as the gold standard to compare and validate the
microchip counts. (a) Microchip measurements highly correlated with FACSCalibur measurements when conducted at an established hospital setting
at BWH (y = 0.86x+304, correlation coefficient: 0.94, p,0.01). (b) When the microchips were shipped to Tanzania and the measurements were
performed at MUHAS, a correlation between the microchip CD4 counts and the FACS counts were observed (y = 0.61x+312, correlation coefficient:
0.49, p,0.01). (c) Bland-Altman Analysis between the microchip and FACS counts did not display an evidence for a systematic bias for BWH
measurements. The mean bias was +76 cells per mL of blood in microchip counts compared to FACS counts at BWH. (d) Bland-Altman Analysis
showed a bias towards higher measurements in MUHAS results, while the mean bias was as low as +23 cells per mL of blood in microchip counts
compared to FACS counts.
doi:10.1371/journal.pone.0021409.g004
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designed for POC must be tested under the full conditions of
resource limited settings for reliable evaluation and assessment.
Supporting Information
Figure S1 Fabrication method for the microfluidic
chips. Components (PMMA and double sided adhesive) were
machined by using a 30W CO2 laser cutter and bonded on a glass
slide.
(TIF)
Figure S2 Microfluidic CD4 chip packaging for inter-
continental logistics. (a) The inlet and outlet ports of the
microfluidic chips were sealed with adhesive tapes and vacuum
sealed in packaging. (b) The microfluidic chips were further placed
in parafilm sealed Petri dishes to further enhance the transpor-
tation safety.
(TIF)
Figure S3 A brief description of the surface chemistry
protocol to immobilize antibodies in microfluidic chips.
The surface modification method was based on silane bonding
with an activated glass surface (i.e., 3MPS, GMBS, Neutravidin,
and anti-CD4 antibody). Scale bar is 4 mm.
(TIF)
Table S1 Standard Operation Procedure (SOP) for
fabricating the microfluidic chips prior to applying the
surface chemistry.
(DOC)
Table S2 Standard Operation Procedure (SOP) for
surface chemistry in microfluidic chips at the point of
care prior to blood testing.
(DOC)
Table S3 Standard Operation Procedure (SOP) for
blood testing at the point of care with CD4 counting
microfluidic chips.
(DOC)
Text S1
(DOC)
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